Rothwell, Ben http://orcid.org/0000-0002-0499-6904
Kiff, Christopher http://orcid.org/0000-0002-0859-0231
Ling, Caroline http://orcid.org/0000-0001-7479-493X
Brodtkorb, Thor-Henrik
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Accepted: 30 November 2020
First Online: 17 December 2020
Declarations
:
: This study was funded by Bristol-Myers Squibb.
: Thor-Henrik Brodtkorb, Caroline Ling and Ben Rothwell are full-time employees of RTI Health Solutions, which received funding from Bristol-Myers Squibb to conduct this study. The contract between RTI Health Solutions and the sponsor includes independent publication rights. RTI Health Solutions conducts work for government, public, and private organisations, including pharmaceutical companies. Christopher Kiff is an employee and stockholder of Bristol-Myers Squibb.
: Not applicable.
: Not applicable.
: Not applicable.
: Data from Phase III CheckMate-017 and CheckMate-057 trials are used in these analyses to inform efficacy, safety and health-related quality-of-life inputs. The patient-level data are not publicly available but have been presented in several publications. The trial results supporting these analyses are presented within the article and in the electronic supplementary material.
: The model was developed in Excel and is not publicly available.
: All authors were responsible for conception and design of the research. Economic modelling was carried out by BR and THB; BR and THB were responsible for development of the draft manuscript; all authors were responsible for critical revision of the manuscript for important intellectual content.